198432
Last Update Posted: 2016-03-10
Recruiting has ended
All Genders accepted | 18 Years-70 Years |
130 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Chemoradiotherapy of NSCLC Stage IIIB
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.
Chemotherapy:
C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m²
Radiotherapy:
66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (>= 9MV)
Eligibility
Relevant conditions:
NSCLC Stage IIIB
Concomitant Radiochemotherapy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov